http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 06:02:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/AEON+Biopharma+%28AEON%29+Misses+Q1+EPS+by+29c/26498122.html <p>AEON Biopharma (NYSE: AEON) reported Q1 EPS of ($0.29).</p><p>For earnings history and earnings-related data on AEON Biopharma (AEON) <a href="http://www.streetinsider.com/ec_earnings.php?q=AEON">click here</a>.</p> http://www.streetinsider.com/Earnings/AEON+Biopharma+%28AEON%29+Misses+Q1+EPS+by+29c/26498122.html Fri, 15 May 2026 06:02:54 -0400 AEON http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html <p align="center"><em>- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -</em></p> <p align="center"><em>- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90%</em> <em>-</em></p> <p align="center"><em>- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -</em></p> <p align="justify">IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26494583.html Thu, 14 May 2026 16:05:00 -0400 A.06822034 A.17150087 A.31066700 A.50216269 A.60012014 AEON O.05058026 O.20026344 O.22422661 O.29757805 O.34929518 O.49558857